press release

UCB Agrees to Acquire Ra Pharmaceuticals: Joining Forces to Improve Treatment Options for People Living With Myasthenia Gravis and Other Rare Diseases

 BRUSSELS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 10, 2019-- regulated information – inside information – UCB and Ra Pharmaceuticals Inc. (NASDAQ: RARX, Ra Pharma) announced today their entry into a merger agreement pursuant for which UCB will acquire Ra Pharma. Under the terms of the agreement, Ra Pharma shareholders will receive US$ 48 in cash for each Ra Pharma share at closing. The Boards of Directors of both companies have unanimously approved the transaction, which remains subject to approval by Ra Pharma shareholders and to obtaining antitrust clearance and other customary closing conditions.

Ra Pharma is a clinical-stage biopharmaceutical company leveraging a proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases caused by excessive or uncontrolled activation of the complement system, a critical component of the innate immune system. The company was founded in 2008 and is headquartered in Cambridge, MA, U.S. The company’s ExtremeDiversity™ platform enables the production of synthetic macrocyclic peptides combining the diversity and specificity of antibodies with the pharmacological properties of small molecules….

Icertis Recognized for AI Leadership in Exclusive Forbes AI 50 List

Oct 01, 2019

CLM Front-Runner Lauded for Delivering Business Value by Unleashing Power of AI on Contracts

BELLEVUE, Wash., October 1, 2019 – Icertis, the leading provider of enterprise contract management in the cloud, today announced its inclusion in the inaugural Forbes AI 50 report, the definitive list of America’s most promising companies working with artificial intelligence (AI). Icertis was selected based on its impressive customer base and ability to show demonstrated business value from the application of machine learning and natural language processing to contracting. Selected from hundreds of applicants, Icertis placed 7th on the valuation-ranked list and was the only company to be featured from the fast-growing contract lifecycle management (CLM) market.

“The inherently broad term ‘artificial intelligence’ gets bandied about so often that it can start to feel meaningless and can be trotted out by companies to gussy up even simple data analysis,” said Jillian D’Onfro, writer at Forbes. “To help cut through the noise, Forbes and our data partner Meritech Capital put together a list of private, U.S.-based companies that are wielding artificial intelligence in a meaningful way and demonstrating real business potential from doing so.”…

Peloton Announces Pricing Of Initial Public Offering

NEW YORK, Sept. 25, 2019 /PRNewswire/ -- Peloton Interactive, Inc. today announced the pricing of its initial public offering of 40,000,000 shares of its Class A common stock at a public offering price of $29.00 per share. The shares are expected to begin trading on the Nasdaq Global Select Market on September 26, 2019 under the ticker symbol "PTON." The offering is expected to close on September 30, 2019, subject to the satisfaction of customary closing conditions.

In addition, the underwriters have been granted a 30-day option to purchase up to an additional 6,000,000 shares of Class A common stock from Peloton at the initial public offering price, less underwriting discounts and commissions….